Zai Lab Limited (HKG:9688)

Market Cap	18.67B
Revenue (ttm)	3.44B
Net Income (ttm)	-1.61B
Shares Out	n/a
EPS (ttm)	-14.96
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,358,666
Average Volume	15,216,498
Open	16.91
Previous Close	17.26
Day's Range	16.91 - 17.35
52-Week Range	16.81 - 35.50
Beta	0.85
RSI	22.21
Earnings Date	Nov 6, 2025

About Zai Lab

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacter...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 1,869
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9688

Financial Performance

In 2024, Zai Lab's revenue was $398.99 million, an increase of 49.59% compared to the previous year's $266.72 million. Losses were -$257.10 million, -23.17% less than in 2023.

Financial numbers in USD